dc.contributor.author | Powell, N | |
dc.contributor.author | Ibraheim, H | |
dc.contributor.author | Raine, T | |
dc.contributor.author | Speight, RA | |
dc.contributor.author | Papa, S | |
dc.contributor.author | Brain, O | |
dc.contributor.author | Green, M | |
dc.contributor.author | Samaan, MA | |
dc.contributor.author | Spain, L | |
dc.contributor.author | Yousaf, N | |
dc.contributor.author | Hunter, N | |
dc.contributor.author | Eldridge, L | |
dc.contributor.author | Pavlidis, P | |
dc.contributor.author | Irving, P | |
dc.contributor.author | Hayee, B | |
dc.contributor.author | Turajlic, S | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Lindsay, JO | |
dc.contributor.author | Gore, M | |
dc.coverage.spatial | Netherlands | |
dc.date.accessioned | 2022-08-22T11:00:47Z | |
dc.date.available | 2022-08-22T11:00:47Z | |
dc.date.issued | 2020-07-01 | |
dc.identifier | S2468-1253(20)30014-5 | |
dc.identifier.citation | The Lancet Gastroenterology & Hepatology, 2020, 5 (7), pp. 679 - 697 | en_US |
dc.identifier.issn | 2468-1253 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5289 | |
dc.identifier.eissn | 2468-1253 | |
dc.identifier.eissn | 2468-1253 | |
dc.identifier.doi | 10.1016/S2468-1253(20)30014-5 | |
dc.description.abstract | Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis. In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis. | |
dc.format | Print | |
dc.format.extent | 679 - 697 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER INC | en_US |
dc.relation.ispartof | The Lancet Gastroenterology & Hepatology | |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_US |
dc.subject | Adrenal Cortex Hormones | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Antineoplastic Agents, Immunological | |
dc.subject | Consensus | |
dc.subject | Endoscopy | |
dc.subject | Endoscopy, Digestive System | |
dc.subject | Enterocolitis | |
dc.subject | Gastroenterology | |
dc.subject | Gastrointestinal Diseases | |
dc.subject | Guidelines as Topic | |
dc.subject | Humans | |
dc.subject | Infliximab | |
dc.subject | Lactoferrin | |
dc.subject | Leukocyte L1 Antigen Complex | |
dc.subject | Neoplasms | |
dc.subject | Patient Care Management | |
dc.subject | Societies, Medical | |
dc.subject | Tumor Necrosis Factor-alpha | |
dc.subject | United Kingdom | |
dc.title | British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-01-21 | |
dc.date.updated | 2022-08-22T11:00:22Z | |
rioxxterms.version | AM | en_US |
rioxxterms.versionofrecord | 10.1016/S2468-1253(20)30014-5 | en_US |
rioxxterms.licenseref.startdate | 2020-07-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/32553146 | |
pubs.issue | 7 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 5 | |
dc.contributor.icrauthor | Turajlic, Samra | |
dc.contributor.icrauthor | Larkin, James | |
icr.provenance | Deposited by Mr Arek Surman on 2022-08-22. Deposit type is initial. No. of files: 1. Files: Lindsay_BSG endorsed guidance enterocolitis_Accepted_2020.pdf | |